NEW YORK (TheStreet) -- Catalyst Pharmaceutical Partners (CPRX) shares are up 14.2% to $3.41 on Tuesday after ROTH Capital raised the company's price target to $6 from $5 and reiterated its "buy" rating.
The upgraded outlook stems from Catalyst's positive phase III study results of Firdapse, a treatment for Lamber-Eaton Myasthenic Syndrome.
Some analysts believe that this news will lead to a prohibitive price tag of between $60,000 and $80,000 a year for the treatment.
TheStreet's Adam Feuerstein discusses the implications of the study results in depth here.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.